Skip to main content
Purple Biotech Ltd. logo

Purple Biotech Ltd. — Investor Relations & Filings

Ticker · PPBT ISIN · IL0007650166 TA Manufacturing
Open in API
Filings indexed 1,071 across all filing types
Latest filing 2025-03-10 Annual Report
Country IL Israel
Listing TA PPBT

About Purple Biotech Ltd.

https://purple-biotech.com/

Purple Biotech Ltd. is a clinical-stage company that develops first-in-class therapies for cancer patients. The company focuses on advancing treatments designed to overcome tumor immune evasion and drug resistance, with the goal of providing effective and durable therapeutic solutions.

Recent filings

Filing Released Lang Actions
Annual report for 2024 on form 20F
Annual Report Classification · 100% confidence The document is a Form 20-F filed with the United States SEC for the fiscal year ended December 31, 2024. Form 20-F is an annual report filed by foreign private issuers, equivalent to the 10-K annual report filed by U.S. domestic companies. The document includes detailed sections such as financial statements, management discussion, corporate governance, and other comprehensive disclosures typical of an annual report. The length of the document (15,000 characters) and the presence of extensive content confirm it is the full report, not just an announcement or certification. Therefore, the document is classified as an Annual Report (10-K equivalent).
2025-03-10 Hebrew (modern)
Annual report for 2024 on form 20F
Report Publication Announcement Classification · 98% confidence The document is a filing notification submitted to the Israel Securities Authority (ISA) and the Tel Aviv Stock Exchange (TASE). The key phrase is: "Attached hereto is a report on *Annual report for 2024 on form 20F*". This indicates that the document itself is an announcement about the publication of an annual report (Form 20-F, which is the foreign equivalent of a 10-K for foreign private issuers). Since the document is short and primarily serves to announce the attachment/availability of the main report, it fits the definition of a Report Publication Announcement (RPA) according to the 'MENU VS MEAL' rule. Although the content relates to an Annual Report (10-K), the document type is the announcement itself.
2025-03-10 English
Purple Biotech Reports Fourth Quarter and Full-Year 2024 Financial Results
Earnings Release Classification · 100% confidence The document is titled "Purple Biotech Reports Fourth Quarter and Full-Year 2024 Financial Results" and contains detailed financial figures for the three and twelve months ended December 31, 2024, including Research and Development Expenses, Operating Loss, and Net Loss. It also discusses clinical trial updates and corporate highlights. This structure—announcing period-specific financial results with accompanying operational updates—is characteristic of an Earnings Release (ER). While it contains comprehensive financial data, the format is a press release announcing the results, not the full, audited Annual Report (10-K) or a comprehensive Interim Report (IR). Since it explicitly reports on the full year's results and is structured as the initial public announcement of these figures, ER is the most appropriate classification. Q4 2024
2025-03-10 English
Purple Biotech Reports Fourth Quarter and Full-Year 2024 Financial Results
Report Publication Announcement Classification · 98% confidence The document explicitly states it is a 'Report of Periodic or Interim Report' filed with the Israel Securities Authority (ISA) and the Tel Aviv Stock Exchange (TASE). Crucially, the text contains the phrase: 'Attached hereto is Purple Biotech Reports Fourth Quarter and Full-Year 2024 Financial Results' followed by a reference to an attached PDF file. Since the document itself is short (2186 chars) and serves primarily to announce the availability of the detailed financial results report rather than containing the full results, it fits the definition of a Report Publication Announcement (RPA). If the attached PDF were provided, it would likely be classified as an Interim Report (IR) or Annual Report (10-K), but this wrapper document is an announcement of publication.
2025-03-10 English
The company's financial results for 2024 were reported abroad
Regulatory Filings Classification · 95% confidence The document is very short (325 characters) and contains a brief notice about the company's financial results being reported abroad. It does not contain any actual financial data, detailed analysis, or substantive report content. It appears to be a regulatory or compliance announcement rather than the report itself. There is no indication of detailed financial statements or management discussion. Therefore, it fits best as a Regulatory Filing (RNS) under the fallback category for miscellaneous filings that do not fit other specific categories.
2025-03-10 Hebrew (modern)
Purple Biotech Granted New U.S. Patent for NT219 in Combination with EGFR Antibody Therapy
Regulatory Filings Classification · 99% confidence The document is explicitly titled 'FORM 6-K' and is filed 'Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934' by a 'Foreign Private Issuer'. Form 6-K filings are used to report material information that the company is required to disclose to its home country's regulators or stock exchange, or that it makes public in its home country. This type of filing does not map directly to the standard US periodic reports (like 10-K or 10-Q) or specific event filings (like DEF 14A or 8-K). Since the content is a press release announcing a patent grant, and it is submitted on a Form 6-K, it represents a general regulatory disclosure that doesn't fit the more specific categories like ER, CAP, or LTR. Therefore, the most appropriate classification, following the provided definitions, is the general fallback category for miscellaneous regulatory filings that do not fit elsewhere, which is 'Regulatory Filings' (RNS). The document length is substantial (14,526 chars), so it is not an RPA.
2025-03-05 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.